Le Lézard
Classified in: Health
Subject: VET

Seraphina Therapeutics Partners with Grey Team to Support the Health of Military Veterans


Award-winning fatty15 supplement now part of Operation Phoenix to support the health and wellness of active-duty soldiers and military veterans

BOCA RATON, Fla., June 30, 2022 /PRNewswire-PRWeb/ -- Two veteran-founded teams are combining forces to support the health of post-combat active duty military soldiers and veterans with post-traumatic stress disorder and traumatic brain injuries. While approximately 15% of veteran and military populations have had post-traumatic stress disorder (also called PTSD), the prevalence of PTSD more than doubles to 37% among those with traumatic brain injuries.

"The latest statistics show that, due to invisible injuries related to PTSD, it is six times more dangerous for an American soldier to return home from war than it is for him or her to be actively engaged in combat," shared, Cary Reichbach, U.S. Army Veteran and Founder of Grey Team, "Our job is to help our veterans receive the care they deserve, and to provide peace, passion and fulfillment."

Grey Team, a U.S. non-profit organization whose mission is to improve the personal health and wellness of both active-duty soldiers and military veterans, uses a combination of holistic healing technologies as well as reinstating a passion of life and purpose, to completely redefine what it means to be a U.S. military veteran. Grey Team has a special program, called Operation Phoenix, which helps military veterans learn to effectively train their minds and bodies, optimize their nutrition, decelerate their "fight or flight" response, and enable psychological recovery from the effects of war.

In support of Operation Phoenix, Grey Team is working with Seraphina Therapeutics, which is co-founded by a military family and husband-wife, physician-scientist team. Seraphina is providing fatty15, their award-winning pure C15:0 supplement, to help support the health and wellness of Operation Phoenix participants. C15:0, also called pentadecanoic acid, is an odd-chain saturated fatty acid that has recently emerged as the first essential fatty acid to be discovered since omega-3 and omega-6.

While fatty15 has been shown to improve metabolic, immune, heart and liver health at the cellular level by strengthening cell membranes and repairing mitochondria, it also naturally activates receptors (called PPAR alpha and delta) throughout the body and brain that can provide benefits relevant to protecting brain health and better handling stress.

"In addition to the growing science around how C15:0 can support both physical and mental health, we continue to receive inspiring testimonials from our customers, including fellow veterans, on how fatty15 is helping to improve their lives," shared Dr. Eric Venn-Watson, who is Seraphina Therapeutics' co-founder, a Navy physician, and a 3-war combat veteran. "We are proud to be partnering with Grey Team on Operation Phoenix to support the long-term health and welfare of our military and veteran communities."

The origin story behind C15:0 has important ties to the military. C15:0 was initially discovered as an essential nutrient by Dr. Stephanie Venn-Watson while working to continually improve the health and welfare of U.S. Navy dolphins. This discovery, and how helping Navy dolphins may just help save the world, was recently featured as a TEDx San Diego talk.

Grey Team, a U.S. non-profit organization whose mission is to improve the personal health and wellness of both active-duty soldiers and military veterans. Grey Team's highly successful Operation Phoenix (the "Operation") leverages the most cutting-edge medical, nutritional, and wellness technologies to support the rehabilitation and wellness of both active-duty soldiers and military veterans. The Operation has helped alleviate mental and physical suffering caused by post-traumatic stress disorder, traumatic brain injuries, chronic physical pain, and lifestyle choices. More information can be found at http://www.greyteam.org.

Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics. Through rigorous breakthrough science, the company develops fatty acid supplements, food fortifiers, and nutritional interventions to strengthen cells, keep mitochondria working and advance cellular homeostasis to counter age-related breakdown. With its team of industry-leading scientists, Seraphina Therapeutics challenges long-held approaches to nutrition, enabling the creation of novel health products designed to support quality of life. For more information, please visit seraphinatherapeutics.com and fatty15.com.

Media Contact

GR0 Agency, GR0, (310) 439-1887, [email protected]

 

SOURCE Seraphina Therapeutics


These press releases may also interest you

at 02:30
111, Inc. ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for...

at 02:30
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports many presentations including new RefluxStoptm real-world data from over 200 patients at five hospitals across Europe, were presented in...

at 02:17
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 02:05
Genflow...

at 02:00
Leading scientists, philanthropists, and policymakers from around the world are coming together in Denmark at the Global Science Summit, hosted by the Novo Nordisk Foundation as part of the organisation's 100-year anniversary. The goal is to explore...

at 01:00
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on...



News published on and distributed by: